Equities research analysts at StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX – Get Free Report) in a research report issued on Thursday. The brokerage set a “hold” rating on the stock.
Brooklyn ImmunoTherapeutics Stock Performance
Brooklyn ImmunoTherapeutics stock opened at $1.31 on Thursday. The stock has a fifty day moving average of $1.74 and a two-hundred day moving average of $1.96. The company has a market capitalization of $77.06 million, a price-to-earnings ratio of -0.58 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a fifty-two week low of $0.17 and a fifty-two week high of $10.10.
About Brooklyn ImmunoTherapeutics
Recommended Stories
- Five stocks we like better than Brooklyn ImmunoTherapeutics
- What is the Dow Jones Industrial Average (DJIA)?
- How Much Can You Make in Stocks in One Month?
- Using the MarketBeat Stock Split Calculator
- This Is the Top Large-Cap Stock Insiders Are Buying
- Industrial Products Stocks Investing
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.